A genome-wide association study of bronchodilator response in Latinos implicates rare variants

Drake, K. A.; Torgerson, D. G.; Gignoux, C. R.; Galanter, J. M.; Roth, L. A.; Huntsman, S.; Eng, C.; Oh, S. S.; Yee, S. W.; Lin, L.; Bustamante, C. D.; Moreno-Estrada, A.; Sandoval, K.; Davis, A.; Borrell, L. N.; Farber, H. J.; Kumar, R.; Avila, P. C.; Brigino-Buenaventura, E.; Chapela, R.; Ford, J. G.; Lenoir, M. A.; Lurmann, F.; Meade, K.; Serebrisky, D.; Thyne, S.; Rodriguez-Cintron, W.; Sen, S.; Rodriguez-Santana, J. R.; Hernandez, R. D.; Giacomini, K. M.; Burchard, E. G.

J Allergy Clin Immunol. 2013 Sep 3; 133(2):370-378.e15

Abstract

BACKGROUND: The primary rescue medication to treat acute asthma exacerbation is the short-acting beta2-adrenergic receptor agonist; however, there is variation in how well a patient responds to treatment. Although these differences might be due to environmental factors, there is mounting evidence for a genetic contribution to variability in bronchodilator response (BDR). OBJECTIVE: To identify genetic variation associated with bronchodilator drug response in Latino children with asthma. METHODS: We performed a genome-wide association study (GWAS) for BDR in 1782 Latino children with asthma using standard linear regression, adjusting for genetic ancestry and ethnicity, and performed replication studies in an additional 531 Latinos. We also performed admixture mapping across the genome by testing for an association between local European, African, and Native American ancestry and BDR, adjusting for genomic ancestry and ethnicity. RESULTS: We identified 7 genetic variants associated with BDR at a genome-wide significant threshold (P < 5 x 10(-8)), all of which had frequencies of less than 5%. Furthermore, we observed an excess of small P values driven by rare variants (frequency, <5%) and by variants in the proximity of solute carrier (SLC) genes. Admixture mapping identified 5 significant peaks; fine mapping within these peaks identified 2 rare variants in SLC22A15 as being associated with increased BDR in Mexicans. Quantitative PCR and immunohistochemistry identified SLC22A15 as being expressed in the lung and bronchial epithelial cells. CONCLUSION: Our results suggest that rare variation contributes to individual differences in response to albuterol in Latinos, notably in SLC genes that include membrane transport proteins involved in the transport of endogenous metabolites and xenobiotics. Resequencing in larger, multiethnic population samples and additional functional studies are required to further understand the role of rare variation in BDR.

Read More on PubMed